Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

BAC and GE Healthcare Collaboration Wins Industry Award

Published: Thursday, October 11, 2012
Last Updated: Thursday, October 11, 2012
Bookmark and Share
Collaboration to develop new technologies for the cost-effective manufacture of novel biopharmaceuticals recognized as ‘Collaboration of the Decade - Downstream Processing’ at BPI Awards.

BAC BV has announced that a successful long-term collaboration with GE Healthcare, the healthcare business of GE, to develop innovative purification media for the production of novel types of biopharmaceuticals has been recognized with the “Collaboration of the Decade Award -Downstream Processing” at the BioProcess International Awards 2012.

Since 2006, BAC and GE Healthcare have worked closely together, developing products aimed at improving the efficiency of biopharmaceutical manufacturing.

With a focus on the development of affinity resins for highly efficient purification, the collaboration has led to the commercial launch of seven products which are now used worldwide in the manufacture of potentially life-saving medicines such as coagulation factors, various antibody formats, biosimilars and gene-therapy vectors.

Worldwide demand for biopharmaceuticals is set to increase, driven by an ageing population, rising obesity levels and the global effort to reduce the incidence of vaccine preventable diseases.

Laurens Sierkstra, CEO of BAC, said: “We are delighted to see our joint efforts to enable the development of the latest biotherapeutics recognized by those in the industry. Our on-going collaboration with GE Healthcare has been highly productive and responsive to the needs of end-users.”

Commenting on the award, Dr. Nigel Darby, Vice President of BioTechnologies, GE Healthcare Life Sciences added, “Collaborations between companies with complementary technologies and expertise are vital in making the advances that will help us tackle global challenges such as the increasing burden of disease and cost of healthcare. With global demand for cost effective biotherapeutics set to rise, collaborations like ours that deliver innovative supporting technologies will play an increasingly significant role.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BAC Completes Feasibility Study in Providing Selective Ligands for Genmab’s UniBody® Platform
BAC has successfully completed and delivered positive results from the initial feasibility study of its CaptureSelect® in collaboration with Genmab.
Thursday, September 30, 2010
BAC and Octapharma Extend Collaboration for G-CSF Custom Ligand for Commercial Scale Manufacture
Octapharma to use BAC’s G-CSF CaptureSelect® custom affinity ligand for the purification of recombinant human G-CSF from human cell cultures.
Thursday, August 19, 2010
BAC Affinity Ligand Licensed for Scale-up of LFB Biotechnologies’ Recombinant Factor VIIa
LFB Biotechnologies to use BAC’s anti-FVIIa CaptureSelect ligand for the purification of rhFVIIa from transgenic animals.
Thursday, April 15, 2010
BAC Extends Partnership with GE Healthcare to Launch Alpha-1 Antitrypsin Select
Extension reflects ongoing demand for BAC’s custom ligand and bioprocess products.
Thursday, February 18, 2010
Scientific News
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Editing Gene Mutations in Anemia
Researchers successfully use a new gene editing strategy to correct mutations that cause a form of anemia.
Genes Help Track Odd Migrations of Zika Mosquitoes
Study shows that mosquitoes carrying Zika virus or Dengue fever a genetically distinct around the world.
Nanomedicine Aims to Improve HIV Drug Therapies
New research aims to improve the administration and availability of drug therapies to HIV patients using nanotechnology.
Tumor Markers Reveal Lethality Of Bladder Cancers
Researchers found that detection of certain tumor cells in early stage cancers helps identify high-risk cancers.
Gene Editing Corrects Sickle Cell Mutation
Researchers demonstrate a potential pathway to developing gene-editing treatments for sickle cell disease.
Driving Mosquito Evolution to Fight Malaria
Researchers propose insect repellent in conjunction with insecticides to extend current insecticide lifetime.
Lab-on-a-Chip to Help Detect Cancer
In this podcast, we speak to Gustavo Stolovitsky to learn about his career and the work he is doing at IBM Research.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos